If a Product Has No Marketing Authorisation, What Checks Matter Most?

In the UK pharmacy supply chain, the presence or absence of a valid marketing authorisation (MA) profoundly shapes the controls and checks that dispensaries must apply. When a product lacks MA—commonly referred to as an unlicensed product—pharmacists and supply chain professionals face distinct regulatory and quality assurance challenges. This article unpacks the critical checks for unlicensed products, spotlighting how new digital tools like electronic transmission of prescriptions (e-prescribing) and integrated dispensing workflows help maintain compliance while optimising patient safety.

Understanding Marketing Authorisation and Its Significance

A marketing authorisation ensures that a medicinal product has been assessed by the Medicines and Healthcare products Regulatory Agency (MHRA) for safety, quality, and efficacy under defined conditions. Products without this authorisation require special handling since they have not undergone the same regulatory scrutiny. The UK’s MHRA guidance sets out the framework for these cases.

Why does this matter in pharmacy workflow? Because standard dispensing, stock control, and information systems are geared around MA products—including barcode validation, expiry checks, and batch traceability—unlicensed products demand nuanced operational controls to mitigate risks.

Core Concepts: Unlicensed Product Controls, Quality Assurance, and Traceability

When a product is unlicensed, three key regulatory and operational checkpoints rise in importance:

• Unlicensed Product Controls: Confirming the legitimacy and source of the product, ensuring it complies with relevant MHRA regulations and PSNI (Pharmaceutical Services Negotiating Committee) guidance.
• Quality Assurance (QA): Verifying product quality before dispensing, often involving additional checks to compensate for the lack of formal MA validation.
• Traceability Requirements: Recording batch numbers, expiry dates, and supplier details in a way that supports patient safety and pharmacovigilance.

So how do digital tools factor into strengthening these processes in a world increasingly moving away from paper-based prescribing?

Electronic Transmission of Prescriptions (ETP): A Game Changer

With the NHS pushing e-prescribing as the norm, the first point of control for unlicensed medicines has shifted digitally. ETP systems, which replace traditional paper prescriptions with fully electronic ones, enable:

• Seamless Data Capture: Prescriber indications about the use of unlicensed products, special instructions, and reason codes can be coded directly into the electronic message.
• Improved Legibility and Accuracy: Eliminating handwriting errors that can result in dispensing mistakes, especially critical for unlicensed or named-patient medicines.
• Real-Time Validation: Dispensing systems integrated with ETP can flag unlicensed products immediately if they do not meet predefined criteria.

Example:

A GP issues an electronic prescription for a specialised unlicensed cream. The ETP system tags this as an unlicensed product requiring pharmacist approval. The nomination Click for source selected by the patient’s pharmacy ensures the right site receives the prescription, preventing unintended substitutions.

Dispensing Workflow Integration: Strength in Process Connectivity

Dispensing workflow software now often incorporates unlicensed product checks as standard. Integration between electronic prescription data and dispensing modules means the following steps are better aligned with regulatory requirements:

1. Identification: The system clearly flags unlicensed products at the point of entry, triggering mandatory prompts—for example, verifying the patient’s informed consent.
2. Verification and Quality Checks: Pharmacists access embedded checklists and documentation requirements, ensuring that the product originates from an approved licensed manufacturer or supplier—even though it itself lacks MA.
3. Recording & Documentation: Barcode scanning enhances traceability. Since unlicensed products can still carry batch and expiry data, this information is logged, satisfying MHRA pharmacovigilance expectations.
4. Audit Trail Preservation: Automated records track who dispensed what, when, and to whom—essential for defending compliance during inspections or incident investigations.

Concrete Example of Workflow Integration:

Consider a central fulfilment pharmacy using robot-assisted dispensing that incorporates barcode scanning. For unlicensed products:

• The robot places the product separately, flagged for pharmacist review.
• The pharmacist verifies documentation electronically before release.
• Scanning the barcode logs batch and expiry, allowing rapid recall if needed.
• The system prevents accidental inclusion of unlicensed products in regular batches without approval.

Pharmacy Nomination and Demand Forecasting

One subtle but crucial aspect of managing unlicensed products is nomination management via electronic prescriptions. Nomination is the process by which a patient specifies a preferred pharmacy for their prescriptions.

Since unlicensed products often require specific handling, pharmacies undertaking nomination must:

• Hold appropriate licences or agreements to handle unlicensed medicines.
• Forecast demand accurately to maintain necessary stock—important because these products often have longer lead times and must not expire unused.

Modern dispensing systems integrated with ETP enable better demand forecasting by analysing repeat dispensing patterns and flagging slow-moving unlicensed stock well before expiry, optimising inventory and reducing wastage.

Repeat Dispensing Scheduling and Its Particular Demands

Repeat dispensing lets patients get multiple supplies on the basis of one prescription authorised for a set period. Applying this to unlicensed products introduces special challenges:

• Stability Considerations: Unlicensed medicines might have shorter shelf lives or require cold chain; scheduling repeat dispensing must respect these constraints to avoid patient risk.
• Ongoing Clinical Review: Because unlicensed status could change (e.g., product becoming licensed, or new alternatives appearing), the system must flag repeat dispensings for pharmacist review.
• Batch Traceability: Each repeat supply might come from different batches, necessitating robust barcode scanning and record linkage throughout the repeat series.

Robotic Dispensing and Barcode Traceability: Enhancing Accuracy and Safety

Robotic dispensing systems are no longer a futuristic idea but a reality in many UK pharmacies. Their integration with barcode traceability is a major asset for managing unlicensed products:

Benefit Impact on Unlicensed Product Control Automated identification via barcode scanning Ensures batch-specific tracking and confirms correct product and dose Physical separation of products in robotics Prevents mixing unlicensed with licensed stock; flags need for pharmacist override Audit trail management Stores complete record for MHRA inspections and patient safety follow-up

Robotic systems fitted to recognise different labelling patterns, including those of specials manufacturers supplying unlicensed products, mitigate human error and compliance risk.

What Regulatory Requirement is Each Step Satisfying?

To avoid simply creating “logistics” complexity, it’s essential to ask: “What regulatory requirement is this step satisfying?” Here’s a summary:

• Electronic Prescription Flagging: Satisfies MHRA requirements to identify unlicensed medicines and ensure pharmacist oversight.
• Pharmacist Verification Prompts: Ensure informed patient consent and compliance with the Human Medicines Regulations 2012, Schedule 18.
• Barcode Scanning and Record-Keeping: Meets MHRA’s traceability and recall obligations under the Falsified Medicines Directive and UK regulations.
• Demand Forecasting and Inventory Management: Reduces waste and maintains supply chain integrity per PSNI Guidelines on Specials.
• Repeat Dispensing Scheduling Rules: Ensures ongoing safety review in line with clinical governance frameworks.
• Robotic Segregation: Controls potential cross-contamination or dispensing errors, an MHRA expectation for quality assurance.

Conclusion: Not Just Another “Digital Transformation” Buzzword

Managing unlicensed products highlights a sharp divide between retail convenience and clinical governance. Employing e-prescribing and integrated dispensing workflows—complete with barcode traceability and robotics—does not merely “digitally transform” pharmacy; it addresses specific regulatory and patient safety requirements.

By embedding controls that satisfy MHRA and PSNI regulations, pharmacies can confidently dispense unlicensed products while maintaining quality assurance. Moreover, these systems handle the logistics of nomination, demand forecasting, and repeat scheduling with far greater precision than paper-based processes ever could.

Ultimately, the checks that matter most are not just about scanning another barcode or toggling a software flag, but weaving regulatory compliance tightly with clinical oversight to safeguard patients where authorised options do not exist.